Theradiag acquires Prestizia - MarketLine Financial Deals

Theradiag acquires Prestizia

Theradiag acquires Prestizia - MarketLine Financial Deals
Theradiag acquires Prestizia
Published Jun 27, 2012
2 pages — Published Jun 27, 2012
Price US$ 20.00  |  Buy this Report Now

About This Report


Theradiag, a theranostics and in vitro diagnostics company, has acquired Prestizia, a biotechnology company developing microRNA1 technology, from investment fund Holding Incubatrice Biotechnologie et Pharmacie. All entities are based in France.

Document ID
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author

Cite this Report

MarketLine Financial Deals. "Theradiag acquires Prestizia" Jun 27, 2012. Alacra Store. Apr 20, 2018. <>
MarketLine Financial Deals. (2012). Theradiag acquires Prestizia Jun 27, 2012. New York, NY: Alacra Store. Retrieved Apr 20, 2018 from <>
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.